These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

539 related items for PubMed ID: 18025853

  • 1. Cost-effectiveness of percent free PSA for prostate cancer detection in men with a total PSA of 4-10 ng/ml.
    Bermúdez-Tamayo C, Martín Martín JJ, González Mdel P, Pérez Romero C.
    Urol Int; 2007; 79(4):336-44. PubMed ID: 18025853
    [Abstract] [Full Text] [Related]

  • 2. Percent free PSA as an additional measure in a prostate cancer screen.
    Miele ME.
    Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
    [Abstract] [Full Text] [Related]

  • 3. Detection of prostatic carcinoma: the role of TRUS, TRUS guided biopsy, digital rectal examination, PSA and PSA density.
    Men S, Cakar B, Conkbayir I, Hekimoglu B.
    J Exp Clin Cancer Res; 2001 Dec; 20(4):473-80. PubMed ID: 11876539
    [Abstract] [Full Text] [Related]

  • 4. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
    Haese A, Dworschack RT, Partin AW.
    J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
    [Abstract] [Full Text] [Related]

  • 5. Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day).
    Srinualnad S, Charoenkraikamol C, Toraksa S, Uiprasertkul M, Amornvesukit T, Taweemonkongsap T, Udompunturak S, Nualyong C, Tantiwong A.
    J Med Assoc Thai; 2006 Jan; 89(1):37-42. PubMed ID: 16583579
    [Abstract] [Full Text] [Related]

  • 6. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
    Mäkinen T, Tammela TL, Hakama M, Stenman UH, Rannikko S, Aro J, Juusela H, Määttänen L, Auvinen A.
    J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [The detection rate of prostate cancer in different prostate-specific antigen (PSA) levels in Chinese men].
    Li M, Na YQ.
    Zhonghua Yi Xue Za Zhi; 2008 Jan 01; 88(1):16-8. PubMed ID: 18346372
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Cost analysis of ultrasound-guided transrectal needle biopsy in prostatic carcinoma].
    Bissoli E, Fandella A, La Torre E, Faggiano L, Anselmo G, Frasson F.
    Radiol Med; 1998 Apr 01; 95(4):353-6. PubMed ID: 9676215
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of Prostate Health Index for prostate cancer detection.
    Nichol MB, Wu J, Huang J, Denham D, Frencher SK, Jacobsen SJ.
    BJU Int; 2012 Aug 01; 110(3):353-62. PubMed ID: 22077934
    [Abstract] [Full Text] [Related]

  • 14. Strategies combining total and percent free prostate specific antigen for detecting prostate cancer: a prospective evaluation.
    Gann PH, Ma J, Catalona WJ, Stampfer MJ.
    J Urol; 2002 Jun 01; 167(6):2427-34. PubMed ID: 11992051
    [Abstract] [Full Text] [Related]

  • 15. Costs and benefits of prostate cancer screening. Investigators of the American Cancer Society--National Prostate Cancer Detection Project.
    Littrup PJ, Goodman AC.
    In Vivo; 1994 Jun 01; 8(3):423-7. PubMed ID: 7803728
    [Abstract] [Full Text] [Related]

  • 16. The electromagnetic detection of prostatic cancer: evaluation of diagnostic accuracy.
    Tubaro A, De Nunzio C, Trucchi A, Stoppacciaro A, Miano L.
    Urology; 2008 Aug 01; 72(2):340-4. PubMed ID: 18336888
    [Abstract] [Full Text] [Related]

  • 17. Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng/mL.
    Canby-Hagino E, Hernandez J, Brand TC, Troyer DA, Higgins B, Ankerst DP, Thompson IM, Leach RJ, Parekh DJ.
    Urology; 2007 Oct 01; 70(4):748-52. PubMed ID: 17991549
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Prostate specific-antigen distribution in asymptomatic Canadian men with no clinical evidence of prostate cancer.
    Chun FK, Perrotte P, Briganti A, Benayoun S, Lebeau T, Ramirez A, Lewinshtein DJ, Valiquette L, Guay JP, Karakiewicz PI.
    BJU Int; 2006 Jul 01; 98(1):50-3. PubMed ID: 16831142
    [Abstract] [Full Text] [Related]

  • 20. Prevalence of prostate cancer at different levels of serum prostate-specific antigen (PSA) and different free: total PSA ratios in a consecutive series of men referred for prostate biopsies.
    Rydén L, Egevad L, Ekman P, Hellström M.
    Scand J Urol Nephrol; 2007 Jul 01; 41(4):302-7. PubMed ID: 17763221
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.